A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (SPRING)
30 novembre 2016 aggiornato da: MedImmune LLC
A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease - GOLD stage II-IV) receiving standard maintenance therapy for the underlying disease condition.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
A Phase 2 double-blind, placebo-controlled study to evaluate the efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease.
The study will have a screening phase of 23 days, treatment phase from Week 1 to 53 and follow-up phase from Week 53 to 69.
Participants will receive either MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53 or matching placebo in the same fashion.
Participants will primarily be assessed for incidence rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Safety will be monitored throughout the study.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
464
Fase
- Fase 2
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Plovdiv, Bulgaria
- Research Site
-
Ruse, Bulgaria
- Research Site
-
Sofia, Bulgaria
- Research Site
-
Stara Zagora, Bulgaria
- Research Site
-
Veliko Tarnovo, Bulgaria
- Research Site
-
-
-
-
-
Iloilo City, Filippine
- Research Site
-
Lipa City, Filippine
- Research Site
-
Quezon City, Filippine
- Research Site
-
-
-
-
-
Daugavpils, Lettonia
- Research Site
-
Riga, Lettonia
- Research Site
-
-
-
-
-
Kaunas, Lituania
- Research Site
-
Klaipeda, Lituania
- Research Site
-
Vilnius, Lituania
- Research Site
-
-
-
-
-
Bialystok, Polonia
- Research Site
-
Gdansk, Polonia
- Research Site
-
Krakow, Polonia
- Research Site
-
Lodz, Polonia
- Research Site
-
Oswiecim, Polonia
- Research Site
-
Poznan, Polonia
- Research Site
-
Wroclaw, Polonia
- Research Site
-
Zgierz, Polonia
- Research Site
-
-
-
-
-
Cambridge, Regno Unito
- Research Site
-
Newcastle upon Tyne, Regno Unito
- Research Site
-
Wolverhampton, Regno Unito
- Research Site
-
-
-
-
-
Brno, Repubblica Ceca
- Research Site
-
Jindrichuv Hradec, Repubblica Ceca
- Research Site
-
Karlovy Vary, Repubblica Ceca
- Research Site
-
Plzen, Repubblica Ceca
- Research Site
-
Praha 10, Repubblica Ceca
- Research Site
-
Strakonice, Repubblica Ceca
- Research Site
-
-
-
-
Arizona
-
Peoria, Arizona, Stati Uniti
- Research Site
-
-
Florida
-
Clearwater, Florida, Stati Uniti
- Research Site
-
-
Georgia
-
Duluth, Georgia, Stati Uniti
- Research Site
-
-
Maine
-
Auburn, Maine, Stati Uniti
- Research Site
-
-
New York
-
Buffalo, New York, Stati Uniti
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti
- Research Site
-
Spartanburg, South Carolina, Stati Uniti
- Research Site
-
-
Texas
-
Boerne, Texas, Stati Uniti
- Research Site
-
-
Virginia
-
Richmond, Virginia, Stati Uniti
- Research Site
-
-
-
-
-
Ivano-Frankivsk, Ucraina
- Research Site
-
Kharkiv, Ucraina
- Research Site
-
Kyiv, Ucraina
- Research Site
-
Odessa, Ucraina
- Research Site
-
Poltava, Ucraina
- Research Site
-
Simferopol, Ucraina
- Research Site
-
Vinnytsya, Ucraina
- Research Site
-
-
-
-
-
Balassagyarmat, Ungheria
- Research Site
-
Budapest, Ungheria
- Research Site
-
Farkasgyepü, Ungheria
- Research Site
-
Komarom, Ungheria
- Research Site
-
Mateszalka, Ungheria
- Research Site
-
Matrahaza, Ungheria
- Research Site
-
Mosonmagyarovar, Ungheria
- Research Site
-
Nagykanizsa, Ungheria
- Research Site
-
Szikszo, Ungheria
- Research Site
-
Tatabanya, Ungheria
- Research Site
-
Torokbalint, Ungheria
- Research Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 45 anni a 75 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Age 45 through 75 years
- Predicted (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II, III, and IV) at Screening
- History of previous acute exacerbations of chronic obstructive pulmonary disease (AECOPD) 12 months prior to Screening
- Clinically stable and free from an AECOPD for 8 weeks prior to Day 1
- Current smoker or ex-smoker with a tobacco history of more than or equal to (>=) 10 pack-years.
Exclusion Criteria:
- Past or present disease or disorder,
- Significant or unstable ischemic heart disease etc
- Known history of allergy or reaction to any component of the investigational manufacturing product (IMP)
- Past or current malignancy within the past 5 years
- Subjects have had a chest x-ray or Computed Tomography (CT) scan suggestive of malignancy or tuberculosis (TB).
- Use of immunosuppressive medication receipt of any biologic agent.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
|
Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
|
|
Sperimentale: MEDI8968 600 mg IV, 300 mg SC
MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
|
MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Lasso di tempo: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
The severity of an AECOPD is defined as: Moderate exacerbations require treatment with systemic corticosteroids, and or antibiotics.
Severe exacerbations require hospitalization.
The AECOPD rate was analyzed using a Poisson Regression model adjusted for over dispersion with number of exacerbations as the outcome and the log of follow-up time as an offset variable, with covariates for treatment group (MEDI8986, placebo), background maintenance therapy and previous exacerbations.
Mean exacerbations were presented as number of exacerbations/year.
|
Day 1 up to 393
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean Rate of Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Lasso di tempo: Day 1 up to 393
|
An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
Severe exacerbations require hospitalization.
The AECOPD rate was analyzed using a Poisson Regression model adjusted for over dispersion with number of exacerbations as the outcome and the log of follow-up time as an offset variable, with covariates for treatment group (MEDI8986, placebo), background maintenance therapy and previous exacerbations.
Mean exacerbations were presented as number of exacerbations/year.
|
Day 1 up to 393
|
|
Time to First Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
Lasso di tempo: Day 1 up to 393
|
Time to first worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.
The severity of an AECOPD is defined as: Mild exacerbations require treatment with an increase in usual therapy, e.g., increase use of short acting bronchodilators.
Moderate exacerbations require treatment with systemic corticosteroids, and or antibiotics.
Severe exacerbations require hospitalization.
|
Day 1 up to 393
|
|
Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Subscales Scores at Week 53
Lasso di tempo: Baseline and Week 53
|
The SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease).
Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100.
The total score and domain score are derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.
|
Baseline and Week 53
|
|
Percentage of Participants With Improvement in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total Score
Lasso di tempo: Week 53
|
The SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease).
Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100.
The total score and domain score are derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.
A 4-point change in total score demonstrates a clinically meaningful change, while an 8-point change and a 12-point change are interpreted as a moderate and large change in health status, respectively.
|
Week 53
|
|
Change From Baseline in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Score at Week 53
Lasso di tempo: Baseline and Week 53
|
The BODE index is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the modified medical research council (MMRC) dyspnea scale and the 6-minute walk test.
The MMRC dyspnea scale is a 5-point scale that measures the level of dyspnea (trouble breathing) experienced by participants where score range is 0 (none) to 4 (very severe).
BODE score is derived into a score range of 0 (healthy) to 10 (severe COPD).
|
Baseline and Week 53
|
|
Percentage of Participants With Improvement in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Score
Lasso di tempo: Baseline and Week 53
|
The BODE index is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the modified medical research council (MMRC) dyspnea scale and the 6-minute walk test.
The MMRC dyspnea scale is a 5-point scale that measures the level of dyspnea (trouble breathing) experienced by participants where score range is 0 (none) to 4 (very severe).
BODE score is derived into a score range of 0 (healthy) to 10 (severe COPD).
Negative change score signifies improvement compared to baseline.
Number of participants with improvement in BODE score compared to baseline were reported.
|
Baseline and Week 53
|
|
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Lasso di tempo: Day 1 up to Week 69
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between administration of study drug and up to Week 69 that were absent before treatment or that worsened relative to pre-treatment state.
TEAEs reported below included both SAEs and non-serious AEs.
|
Day 1 up to Week 69
|
|
Observed Serum Concentrations of MEDI8968
Lasso di tempo: Pre-dose (Baseline), Post-dose on Week 53
|
Pre-dose (Baseline), Post-dose on Week 53
|
|
|
Number of Participants Exhibiting Anti-Drug Antibodies for MEDI8968 at Any Visit
Lasso di tempo: Day 1 up to Week 69
|
Anti-drug antibodies for MEDI8968 were analyzed for participants who received placebo or MEDI8968 as per planned analysis.
|
Day 1 up to Week 69
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Direttore dello studio: Rene Van Der Merwe, MBChB, MFPM, MedImmune Ltd
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 novembre 2011
Completamento primario (Effettivo)
1 febbraio 2014
Completamento dello studio (Effettivo)
1 febbraio 2014
Date di iscrizione allo studio
Primo inviato
6 ottobre 2011
Primo inviato che soddisfa i criteri di controllo qualità
6 ottobre 2011
Primo Inserito (Stima)
7 ottobre 2011
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
30 gennaio 2017
Ultimo aggiornamento inviato che soddisfa i criteri QC
30 novembre 2016
Ultimo verificato
1 novembre 2016
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CD-RI-MEDI8968-1103
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .